Direct Biologics

About Direct Biologics

Direct Biologics manufactures extracellular vesicle (EV) products derived from adult human mesenchymal stem/stromal cells, which contain bioactive molecules with therapeutic potential for regenerative medicine. Their offerings, including ExoFlo, aim to improve treatment outcomes for various diseases by providing clinically validated regenerative biologic solutions.

```xml <problem> Many diseases lack effective treatments that promote tissue regeneration and repair. Traditional therapies often manage symptoms without addressing the underlying cellular damage or loss of function. This unmet need drives the search for innovative regenerative medicine solutions. </problem> <solution> Direct Biologics develops and manufactures extracellular vesicle (EV) products derived from adult human mesenchymal stem/stromal cells (MSCs). These EVs contain bioactive molecules that stimulate regenerative processes within the body. Their lead product, ExoFlo, is designed to improve treatment outcomes for various diseases by delivering clinically validated regenerative biologic solutions. Direct Biologics leverages its expertise in cellular and regenerative therapies to produce high-quality and safe EVs. </solution> <features> - Extracellular vesicles (EVs) derived from adult human mesenchymal stem/stromal cells (MSCs) - cGMP manufacturing processes to ensure product quality and consistency - Bioactive molecules with therapeutic potential for regenerative medicine - ExoFlo product for various disease applications </features> <target_audience> The primary target audience includes medical professionals and researchers in the field of regenerative medicine seeking advanced biologic products for therapeutic applications. </target_audience> ```

What does Direct Biologics do?

Direct Biologics manufactures extracellular vesicle (EV) products derived from adult human mesenchymal stem/stromal cells, which contain bioactive molecules with therapeutic potential for regenerative medicine. Their offerings, including ExoFlo, aim to improve treatment outcomes for various diseases by providing clinically validated regenerative biologic solutions.

How much funding has Direct Biologics raised?

Direct Biologics has raised $35.1M.

Funding
$35.1M
Employees
56 employees
DB

Direct Biologics

Direct Biologics manufactures extracellular vesicle (EV) products derived from adult human mesenchymal stem/stromal cells, which contain bioactive molecules with therapeutic potential for regenerative medicine. Their offerings, including ExoFlo, aim to improve treatment outcomes for various diseases by providing clinically validated regenerative biologic solutions.

563K+ followers
Updated 2 months ago

Funding

$35.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Many diseases lack effective treatments that promote tissue regeneration and repair. Traditional therapies often manage symptoms without addressing the underlying cellular damage or loss of function. This unmet need drives the search for innovative regenerative medicine solutions.

Solution

Direct Biologics develops and manufactures extracellular vesicle (EV) products derived from adult human mesenchymal stem/stromal cells (MSCs). These EVs contain bioactive molecules that stimulate regenerative processes within the body. Their lead product, ExoFlo, is designed to improve treatment outcomes for various diseases by delivering clinically validated regenerative biologic solutions. Direct Biologics leverages its expertise in cellular and regenerative therapies to produce high-quality and safe EVs.

Target Audience

The primary target audience includes medical professionals and researchers in the field of regenerative medicine seeking advanced biologic products for therapeutic applications.

Features

  • Extracellular vesicles (EVs) derived from adult human mesenchymal stem/stromal cells (MSCs)
  • cGMP manufacturing processes to ensure product quality and consistency
  • Bioactive molecules with therapeutic potential for regenerative medicine
  • ExoFlo product for various disease applications
1
This profile is AI-generated and may contain inaccuracies.